Biogen (NASDAQ:BIIB) Sets New 1-Year High - Time to Buy?

Key Points

• Biogen shares reached a new 52-week high, trading as high as $220.14 and gaining 2.7% during the session. The stock has a market capitalization of approximately $32.27 billion.
• Analysts remain broadly positive, with a consensus “Moderate Buy” rating and an average price target of $227.07; recent targets range from $231 to $300.
• Biogen exceeded quarterly expectations, reporting $3.60 in earnings per share versus a $2.94 consensus estimate and $2.74 billion in revenue, up 3.4% year over year. Institutional investors own approximately 87.93% of the company’s shares.

Biogen Inc. (NASDAQ:BIIB - Get Free Report) shares hit a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $220.14 and last traded at $219.1490, with a volume of 114851 shares. The stock had previously closed at $212.55.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on BIIB shares. HC Wainwright increased their target price on shares of Biogen from $237.00 to $251.00 and gave the company a "buy" rating in a research report on Thursday, July 30th. Morgan Stanley boosted their price target on shares of Biogen from $222.00 to $231.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 30th. Piper Sandler reiterated an "overweight" rating on shares of Biogen in a report on Tuesday, July 14th. Oppenheimer reissued an "outperform" rating and issued a $300.00 target price on shares of Biogen in a research note on Wednesday, July 29th. Finally, Needham & Company LLC boosted their target price on Biogen from $255.00 to $256.00 and gave the stock a "buy" rating in a report on Monday, June 29th. One analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating, thirteen have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Biogen presently has an average rating of "Moderate Buy" and a consensus price target of $227.07.

Biogen Trading Up 2.7%

The stock has a market capitalization of $32.27 billion, a price-to-earnings ratio of 38.61, a PEG ratio of 6.48 and a beta of 0.17. The company's 50-day moving average is $204.36 and its 200-day moving average is $193.76. The company has a quick ratio of 1.26, a current ratio of 1.87 and a debt-to-equity ratio of 0.39.

Biogen (NASDAQ:BIIB - Get Free Report) last posted its earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share for the quarter, beating the consensus estimate of $2.94 by $0.66. Biogen had a net margin of 8.32% and a return on equity of 11.18%. The company had revenue of $2.74 billion for the quarter, compared to analyst estimates of $2.46 billion. During the same period in the previous year, the business posted $5.47 EPS. Biogen's revenue was up 3.4% on a year-over-year basis. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. Research analysts anticipate that Biogen Inc. will post 12.39 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Reflection Asset Management acquired a new position in shares of Biogen in the 4th quarter worth approximately $25,000. WPG Advisers LLC boosted its holdings in Biogen by 417.9% in the fourth quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company's stock valued at $26,000 after purchasing an additional 117 shares during the period. Bell Investment Advisors Inc acquired a new stake in Biogen in the 2nd quarter valued at about $27,000. First Horizon Corp purchased a new position in shares of Biogen in the 4th quarter valued at about $30,000. Finally, WFA of San Diego LLC purchased a new position in shares of Biogen in the 2nd quarter valued at about $32,000. Institutional investors and hedge funds own 87.93% of the company's stock.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer's disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company's marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source